California State Teachers Retirement System Raises Stock Position in United Therapeutics Corporation $UTHR

California State Teachers Retirement System grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 55,526.2% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 33,288,952 shares of the biotechnology company’s stock after acquiring an additional 33,229,108 shares during the period. California State Teachers Retirement System owned 0.78% of United Therapeutics worth $18,036,953,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Callan Family Office LLC purchased a new stake in United Therapeutics in the second quarter worth about $1,217,000. Leuthold Group LLC increased its position in United Therapeutics by 41.4% during the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the period. Nicholas Investment Partners LP increased its position in United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock valued at $2,218,000 after purchasing an additional 3,766 shares during the period. Havemeyer Place LP bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $2,189,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of United Therapeutics in the 4th quarter valued at about $633,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $487.61 on Tuesday. The stock has a market capitalization of $20.91 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.43 and a beta of 0.56. United Therapeutics Corporation has a 52 week low of $375.61 and a 52 week high of $609.35. The firm has a 50 day moving average of $524.81 and a 200 day moving average of $540.05.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $6.41 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $482.03, for a total value of $4,000,849.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $21,774,259.16. This trade represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $493.46, for a total value of $4,687,870.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $160,099,642.78. This represents a 2.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 384,575 shares of company stock valued at $204,028,738 in the last three months. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.